Articles On MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals’ continued success in clinical trial tests on COVID-19 patients has seen the company take a significant step towards having its natural supplement “ArtemiC” registered as a medicine in Russia with the anti-inflammatory p...

The proposed joint venture company will be managed by Dr Kopachevskaja and her team with assistance from MGC Pharma’s Europe-based team.

MGC Pharma (ASX:MXC) has established a joint venture for medical products in the Russian market including for its anti-inflammatory product which is a proposed treatment for COVID-19. The European-based biopharma company’s Russian business...

ASX-listed medicinal marijuana company, MGC Pharmaceuticals’ natural supplement “ArtemiC” has emerged as a serious contender in the race to combat the symptoms of COVID-19 following encouraging human clinical trial results in Israel involvi...

Results met FDA primary endpoint of sustained clinical recovery, preventing the need of intensive care in high-risk patients with genetic diversity or invasive mechanical ventilation.

The European-based biopharma company recently received an initial purchase order from LYPHE for 900 units of its affordable Mercury Pharma medicine line of products.

ASX-listed medicinal cannabis player, MGC Pharmaceuticals, has snared a key UK distribution agreement with leading UK medicinal cannabis provider, LYPHE Group, for MGC Pharma’s cannabinoid medicines that will see its products delivered dire...

The European-based biopharma company has already received an initial purchase order from LYPHE for 900 units of its affordable Mercury Pharma medicine line of products.

The company is developing medicines that leverage its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling future medical product sales across the globe.

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed at any time following the presentation.

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses the rebounding cannabis market.  Populating the analysts panel this week is...

Bio-pharma company MGC Pharmaceuticals’ natural supplement “ArtemiC” may end up helping in the global fight against Coronavirus after results from pre-clinical in-vitro laboratory tests in Israel showed a response on human immune function t...

Some elements of the formulation demonstrated an effective response on immune function in a manner considered desirable in the treatment of COVID-19.

Some elements of the formulation demonstrated an effective response on immune function in a manner considered desirable in the treatment of COVID-19.

News that MGC Pharmaceuticals’ (ASX:MXC) phytocannabinoid-derived medical spray could be an effective treatment for COVID-19 sent the stock up almost 41 per cent on Friday morning. Tests conducted by the company at MyPlant Bio in Israel fou...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

ArtemiC is a natural supplement formula based on Artemisinin and Curcumin, along with supporting ingredients Vitamin C and Boswellia serrata, which are natural active ingredients with anti-infective properties.

Summary EU biopharma player MGC Pharmaceuticals announced favourable safety and tolerability results for COVID-19 treatment candidate, ArtemiC in a preclinical study. The Company signed a binding term sheet with Cannvalate Pty Ltd to ac...

Summary EU biopharma player MGC Pharmaceuticals announced favourable safety and tolerability results for COVID-19 treatment candidate, ArtemiC in a preclinical study. The Company signed a binding term sheet with Cannvalate Pty Ltd to ac...

The results follow a pre-clinical study undertaken on nine mice in Israel, with ArtemiC delivering no adverse results in toxicity measures.

MGC Pharmaceuticals (ASX:MXC) has achieved positive safety and efficacy results from a safety and toxicology mouse study for a natural supplement formulation. The pre-clinical study was performed in the Science in Action Laboratory in Ness...

The company creates premium phytocannabinoid-based products from its GMP facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

 It’s been a while since pot stocks have made headlines. The industry as a whole has been fairly quiet lately. Largely overshadowed by the ongoing pandemic and its fallout. That hasn’t stopped MGC Pharmaceuticals Ltd [ASX:MXC] from their pl...

Medicinal Cannabis Clinic provides a range of solutions focused on enabling patient access to affordable and experienced cannabinoid prescribing doctors.

Bio-pharma company MGC Pharmaceuticals (ASX:MXC) has struck a $1.4m deal to acquire Australian clinic business Medicinal Cannabis Clinic and its extensive doctor and patient network. MGC has signed a binding term sheet agreement with parent...

Summary MGC Pharmaceuticals received a cannabis research cultivation permit, allowing the company to continue botanical research projects with RMIT University for anticancer treatments. Preliminary study results highlight that NeuroScie...

MGC Pharmaceuticals continues to kick goals in the medicinal cannabis space in Australia, having clinched a cannabis research cultivation permit.

This permit enables the company to proceed with its botanical research projects in collaboration with Royal Melbourne Institute of Technology (RMIT University), including cultivation and genetics.

MGC Pharmaceuticals (ASX: MXC) has reached yet another regulatory milestone after the biopharmaceutical company confirmed it has been granted a cannabis research cultivation permit by the Australian Office of Drug Control (ODC). The grant f...

One of Australia's top cannabis companies has today received a Cannabis Research Cultivation Permit, allowing the company to commence testing the effects of cannabis on cancer cells. MGC Pharma (ASX: MXC) will now be able to proceed with...

MGC Pharmaceuticals (ASX:MXC) has been granted a Cannabis Research Permit from the Australian Office of Drug Control (ODC). This follows the receipt of the Cannabis Research Licence in 2019. The receipt of a permit enables the company to pr...

The company creates premium phytocannabinoid-based products from its GMP facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

Summary Althea announced the commencement of online sales of medicinal cannabis-based products via Althea Concierge™; share price up by ~9%. The new interactive treatment plan feature permits doctors to issue personalised treatments dir...

Medicinal cannabis producer and developer MGC Pharma (ASX: MXC) will see its logistics processes streamlined following the granting of a new import licence. Issued by the Australian Office of Drug Control (ODC) the import licence will ena...

The licence allows for the importation of any MGC Pharma Schedule-4 and Schedule-8 medicinal cannabis products into Australia.

The trial expansion will provide wider statistical data required for the application of marketing authorisation for ArtemiC with the US Food and Drug Administration and the European Medicines Agency registration.

MGC Pharmaceuticals (ASX: MXC) has confirmed the footprint of a Phase II trial into the efficacy of its ArtemiC anti-inflammatory medicated spray on the COVID-19 virus will be expanded to include the Mahatma Gandhi Mission Medical College a...

The licence reinforces MGC Pharma's ability to deliver on its target production of 5,000 units per month by the start of 2021 from existing supply and distribution deals in place.

Onassis is led by highly experienced entrepreneur Eliron Yaron who has decades of capital markets experience and commercialising businesses.

Europe-based bio-pharma company MGC Pharma (ASX:MXC) has completed a deal to sell its MGC Nutraceuticals business to US health and wellness group Onassis Holdings Corp. The transaction will see Onassis take 100 per cent ownership of the Nut...

MGC Pharma secures a second international partnership, signing a binding term sheet. Europe-based bio-pharma company MGC Pharma (ASX:MXC) has secured a second international partnership in as many months, this time with Israeli cannabis comp...

IM Cannabis Corp will be responsible for the importation, commercialisation, promotion and distribution of CannEpil® in Israel, with MGC Pharma to apply for registration under early patient access scheme.

Optimism is returning to the sleep apnoea market as Somnomed (ASX:SOM) says the nightmares that prompted a $15.5m capital raising in March haven’t returned. In fact, “trading has been better than expected and forecast” since the company rai...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

THC Global Group (ASX: THC) will pay $3 million in shares and cash to acquire the Tetra Health network of clinics which provide access to legal medicinal cannabis. Tetra’s network comprises over 630 referring and prescribing physicians, as...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 61 were in positive territory over the last fortnight, 10 were flat and 66 saw their share prices fall. Code Name...

Medicinal cannabis company MGC Pharma (ASX:MXC) is staying busy during the pandemic, after getting ethics approval from a second hospital in Israel to run a phase II clinical trial on COVID-19 patients. The company also announced firm commi...

MGC Pharmaceuticals (ASX: MXC) is about to kick-off a phase II clinical trial evaluating a natural anti-infective drug on COVID-19 patients. Israel’s Nazareth Hospital Human Research Ethics Committee has given the go-ahead for MGC to procee...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...